Aurinia Pharmaceuticals Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.auriniapharma.com

Moat Score

Market Cap $1.15B
PE 200
Debt -
Cash $83.43M
EV -
FCF $44.11M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$5.75M
EBIT	$7.45M
ROE	2%
ROA	1%
FCF	$44.11M
Equity	$377.48M
Growth Stability	1
PE	199.62
PB	3.04
P/FCF	26.03
P/S	4.88
Price/Cash	0.07
Net Margins	2%
Gross Margins	88%
Op. Margins	3%
Sales Growth YoY	33%
Sales Growth QoQ	-12%
Sales CAGR	244%
Equity CAGR	11%
Earnings Growth YoY	-105%

Earnings Growth QoQ	-90%
Sales CAGR 5Y	228%
Equity CAGR 5Y	4%
Earnings CAGR 3Y	48%
Sales CAGR 3Y	48%
Equity CAGR 3Y	-6%
Market Cap	$1.15B
Revenue	$235.13M
Assets	$550.65M
Cash	$83.43M
Shares Outstanding	140.88M
Moat Score	33%
Working Capital	348.83M
Current Ratio	4.57
Gross Profit	$206.89M
Shares Growth 3y	0%
Equity Growth QoQ	-3%
Equity Growth YoY	-0%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

SEC Filings

Direct access to Aurinia Pharmaceuticals Inc. (AUPH) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Aurinia Pharmaceuticals Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aurinia Pharmaceuticals Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aurinia Pharmaceuticals Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aurinia Pharmaceuticals Inc..

Years

Calculation mode

= $441M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$44M	$44M	$44M	$44M	$44M	$44M	$44M	$44M	$44M	$44M	$44M	$441M
DCF		$40M	$36M	$33M	$30M	$27M	$25M	$23M	$21M	$19M	$17M	$170M
Value	$441M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-14K%	-39K%	-205%	-397%	-81%	-44%	2%	2%
ROA	-	-	-	-27%	-22%	-33%	-23%	-14%	1%	1%
ROE	-	-	-	-41%	-25%	-38%	-27%	-21%	2%	2%

Bad Net Margins (2.45%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-31%	16K%	-9%	194%	31%	34%	228%
Earnings YoY growth	-	204%	-9%	93%	-17%	76%	-40%	-28%	-107%	-
Equity YoY growth	-	-	-24%	120%	37%	17%	-15%	-7%	-0%	4%
FCF YoY growth	-	-	-	23%	18%	109%	-49%	-57%	-229%	-